Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00030043 · ClinicalTrials.gov registry record · Phase 1
An Implant for Hearing Loss Due to Removal of Neurofibromatosis 2 Tumors
A Phase 1 study of Neurofibromatosis 2, sponsored by FDA Office of Orphan Products Development.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
- 3
- Study locations
NCT00030043 is a Phase 1 study of Neurofibromatosis 2 that has completed, run by FDA Office of Orphan Products Development. The registered enrollment target is 10 participants, below the 6,705-participant average among 3 other Neurofibromatosis 2 trials with a reported enrollment target (100% lower). The trial reports 3 study locations across 2 states.
The verdict
NCT00030043, a Phase 1 study of Neurofibromatosis 2, has completed, sponsored by FDA Office of Orphan Products Development.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
- 3
- Study locations
Study Summary
This is a study to gather some information on the safety and efficacy of the penetrating auditory brainstem implant (PABI) in patients with neurofibromatosis type 2.
Conditions Studied
Interventions
- DEVICE Penetrating auditory brainstem implant
Study Locations (3)
California
- House Ear Institute - Los Angeles
- Huntington Medical Research Institutes - Pasadena
Colorado
- Cochlear Corporation - Englewood
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2001-09 |
| Est. Completion | 2003-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00030043
The ClinicalTrials.gov registry entry for NCT00030043 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 6,705-participant average among 3 other Neurofibromatosis 2 trials with a reported enrollment target (100% lower). The listed sponsor is FDA Office of Orphan Products Development, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Neurofibromatosis 2 appearing as the primary indexed condition, and to 1 intervention - of which Penetrating auditory brainstem implant is the first listed.
NCT00030043 reports 3 study locations spanning 2 distinct geographic areas - top geographies include California, Colorado.
Frequently Asked Questions
What is clinical trial NCT00030043 about?
NCT00030043 is a clinical study titled "An Implant for Hearing Loss Due to Removal of Neurofibromatosis 2 Tumors". This is a study to gather some information on the safety and efficacy of the penetrating auditory brainstem implant (PABI) in patients with neurofibromatosis type 2.
What is the current status of trial NCT00030043?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2001-09. Estimated completion is 2003-08.
What conditions does trial NCT00030043 study?
This clinical trial studies the following conditions: Neurofibromatosis 2.
What interventions are being tested in trial NCT00030043?
The interventions under investigation include: Penetrating auditory brainstem implant (DEVICE).
Who is sponsoring clinical trial NCT00030043?
This trial is sponsored by FDA Office of Orphan Products Development, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00030043 being conducted?
This trial has 3 study locations across California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neurofibromatosis 2
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.